BR112021009353A2 - Formulações farmacêuticas para administração subcutânea - Google Patents

Formulações farmacêuticas para administração subcutânea

Info

Publication number
BR112021009353A2
BR112021009353A2 BR112021009353A BR112021009353A BR112021009353A2 BR 112021009353 A2 BR112021009353 A2 BR 112021009353A2 BR 112021009353 A BR112021009353 A BR 112021009353A BR 112021009353 A BR112021009353 A BR 112021009353A BR 112021009353 A2 BR112021009353 A2 BR 112021009353A2
Authority
BR
Brazil
Prior art keywords
subcutaneous administration
pharmaceutical formulations
monophosphate
compositions
weight
Prior art date
Application number
BR112021009353A
Other languages
English (en)
Portuguese (pt)
Inventor
S Locke Charles
Ehab Moussa
Feroz Jameel
Matthew Rosebraugh
F Facheris Maurizio
Nancy Sever
Sven Stodtmann
Z Robieson Weining
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112021009353A2 publication Critical patent/BR112021009353A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021009353A 2018-11-15 2019-11-15 Formulações farmacêuticas para administração subcutânea BR112021009353A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862767546P 2018-11-15 2018-11-15
US201962843945P 2019-05-06 2019-05-06
US201962863101P 2019-06-18 2019-06-18
US201962863113P 2019-06-18 2019-06-18
US201962863093P 2019-06-18 2019-06-18
US201962898214P 2019-09-10 2019-09-10
PCT/US2019/061626 WO2020102628A1 (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Publications (1)

Publication Number Publication Date
BR112021009353A2 true BR112021009353A2 (pt) 2021-11-23

Family

ID=68835352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009353A BR112021009353A2 (pt) 2018-11-15 2019-11-15 Formulações farmacêuticas para administração subcutânea

Country Status (14)

Country Link
US (3) US12251365B2 (https=)
EP (1) EP3880210A1 (https=)
JP (2) JP2022507528A (https=)
KR (1) KR20210091139A (https=)
CN (1) CN113015531A (https=)
AU (2) AU2019379806B2 (https=)
BR (1) BR112021009353A2 (https=)
CA (1) CA3117983A1 (https=)
IL (1) IL282842A (https=)
MX (1) MX2021005776A (https=)
SG (1) SG11202104499RA (https=)
TW (1) TW202031265A (https=)
UY (1) UY38473A (https=)
WO (1) WO2020102628A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
WO2023049534A2 (en) 2021-10-27 2023-03-30 Abbvie Inc. Subcutaneously administered treatments for advanced parkinson's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US3998799A (en) 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US3939253A (en) 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US3891696A (en) 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4065566A (en) 1975-04-17 1977-12-27 Interx Research Corporation N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and derivatives pharmaceutical compositions and methods containing same
US4035507A (en) 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4163058A (en) 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6576766B1 (en) 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CA2490626A1 (en) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
DE602004031134D1 (de) 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ES2360759T3 (es) 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
KR20060108692A (ko) 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
CA2571726C (en) 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007138086A1 (en) 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
KR20090033871A (ko) 2006-06-16 2009-04-06 솔베이 파마슈티칼스 비. 브이 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PL2432454T3 (pl) 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
SG179135A1 (en) 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
PT2640358T (pt) 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
CN103228618B (zh) 2010-12-02 2016-02-17 小野药品工业株式会社 新化合物及其医药用途
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
CN112521305B (zh) 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3116475T3 (da) 2014-03-13 2020-12-07 Neuroderm Ltd Dopa-decarboxylasehæmmersammensætninger
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US20240024338A1 (en) 2016-04-20 2024-01-25 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
EP4295909A3 (en) 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
BR112019001229B1 (pt) 2016-07-22 2022-11-16 Syngenta Participations Ag Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023049534A2 (en) 2021-10-27 2023-03-30 Abbvie Inc. Subcutaneously administered treatments for advanced parkinson's disease

Also Published As

Publication number Publication date
US20250186382A1 (en) 2025-06-12
US20250325507A1 (en) 2025-10-23
WO2020102628A1 (en) 2020-05-22
US20200155578A1 (en) 2020-05-21
EP3880210A1 (en) 2021-09-22
JP2024174894A (ja) 2024-12-17
UY38473A (es) 2020-06-30
US12251365B2 (en) 2025-03-18
KR20210091139A (ko) 2021-07-21
MX2021005776A (es) 2021-07-02
JP2022507528A (ja) 2022-01-18
IL282842A (en) 2021-06-30
AU2019379806A1 (en) 2021-05-27
AU2019379806B2 (en) 2025-08-14
CA3117983A1 (en) 2020-05-22
SG11202104499RA (en) 2021-05-28
TW202031265A (zh) 2020-09-01
AU2025256148A1 (en) 2025-11-13
CN113015531A (zh) 2021-06-22

Similar Documents

Publication Publication Date Title
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BR112022011716A2 (pt) Plaquetas manipuladas para entrega alvejada de um agente terapêutico
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
MA42232A (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
BR112014003640A2 (pt) métodos para perda de peso e composições cetogênicas
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
BR112018010155A2 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
BR112023000220A2 (pt) Formulações de longa ação
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
BR112021009353A2 (pt) Formulações farmacêuticas para administração subcutânea
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
MX2018002997A (es) Composicion para mantener la dominancia de lactobacillus.
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]